From Mechanism to Market
For 20 years Rosa has delivered insights to our clients that would be impossible to obtain in any other way.
PhysioPD Research
PhysioPD™ Research is a proprietary approach that translates the physiology, disease pathophysiology, and drug pharmacology of interest into a customized and interactive mathematical Research Platform. PhysioPD delivers credible insights that would be impossible to obtain in any other way. It is used by scientists and clinicians to clarify the connection between disease mechanisms, therapeutic interventions, and clinical outcomes. The result is that decision-makers have a dramatic increase in confidence to develop successful clinical trials and product submissions.
Learn more about PhysioPD Research
Market Modeling
Rosa Market Modeling credibly identifies what product attributes drive physician uptake. Rosa's proprietary methods and technology can explore a breadth of product profiles and competitive scenarios that would be impossible to explore in any other way. The Market Model is a durable asset that can be used to fine-tune product features and demonstrate the potential commercial demand in a variety of current and future competitive scenarios over multiple years.
Learn more about Market ModelingExplore our Worldwide Webinar Series
Rosa’s "Impact" webinar series is renowned for its informative discussions on the use of computer modeling and simulation within the global research and development community. Register for an upcoming webinar or download a webinar from the archives.
Explore Webinars
Recent Highlights
Rosa & Co. is proud to announce that two posters authored by Rosa scientists will be presented at the upcoming Population Approach Group in Europe (PAGE) virtual meeting.Vincent Hurez, DVM, Ph.D, a Senior Scientist at Rosa & Co., will be pres... Read More
Rosa & Co. announced today the contributions of Dr. Christina Friedrich, Chief Engineer at Rosa, to the article titled, “FDA-Industry Scientific Exchange on assessing quantitative systems pharmacology models in clinical drug development: a meetin... Read More
Rosa & Co. announced today the publication of an abstract titled, “Modeling shows the NK3R antagonist, ACER-801, reduces treatment-induced vasomotor symptoms,” in the 2021 ASCO Meeting Library.Rosa team members Rebecca Baillie, Katherine Kurycki,... Read More
Today, Rosa & Co. announced that Dr. Bill Brastow, Chief Technology Officer at Rosa Market Modeling, will present a webinar entitled “Driving Market Share for Healthcare Products by Integrating Market Modeling” on Wednesday, March 18. Hosted in p... Read More